Page last updated: 2024-12-09

1-(4-methyl-3-nitrophenyl)-3-[(4-methylphenyl)methyl]thiourea

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

## 1-(4-methyl-3-nitrophenyl)-3-[(4-methylphenyl)methyl]thiourea: A Potential Drug Candidate

This long chemical name describes a specific organic compound, a thiourea derivative. While its precise function and importance might depend on the specific research context, here's what we can infer:

**Structure and Properties:**

* **Thiourea derivative:** It belongs to a class of compounds containing a thiourea group (-NH-CS-NH-) which is known for its ability to form hydrogen bonds and interact with biological systems.
* **Aromatic rings:** The presence of two aromatic rings (4-methylphenyl) suggests potential for drug-like properties, including lipophilicity and potential interactions with biological targets.
* **Nitro group:** The nitro group (NO2) is often associated with increased biological activity and can influence the compound's chemical reactivity.

**Potential Applications:**

Based on its structure, this compound could be explored for various research purposes, including:

* **Drug Discovery:** Thiourea derivatives are known for their potential pharmacological activities, ranging from antimicrobial and anticancer to anti-inflammatory effects. This compound could be a potential drug candidate for a specific disease or condition.
* **Biological Research:** It could be used as a tool to study biological processes or as a probe to investigate the activity of enzymes or proteins.
* **Materials Science:** Thiourea derivatives can exhibit interesting properties, such as photoconductivity and luminescence, which may be relevant for developing new materials.

**Importance in Research:**

The exact importance of this specific compound relies on the context of the research. However, the following factors make it potentially interesting:

* **Novel structure:** It combines specific functionalities (thiourea, aromatic rings, nitro group) that could result in unique biological activities.
* **Potential for medicinal chemistry:** Its chemical structure suggests potential as a lead compound for drug discovery.
* **Structural diversity:** The specific chemical structure could be modified further to optimize its properties and explore different areas of research.

**In conclusion,** 1-(4-methyl-3-nitrophenyl)-3-[(4-methylphenyl)methyl]thiourea is a potentially valuable compound for research in various fields. Its importance depends on the specific research question and application.

**To understand its importance fully, more information is needed about the specific research area where this compound is being investigated.** For instance, knowing the specific biological target or the intended application would provide a better understanding of its relevance.

Cross-References

ID SourceID
PubMed CID970622
CHEMBL ID1602768
CHEBI ID107170

Synonyms (11)

Synonym
1-(4-methylbenzyl)-3-(4-methyl-3-nitrophenyl)thiourea
STK456071
n-(4-methylbenzyl)-n'-(4-methyl-3-nitrophenyl)thiourea
MLS000581284
smr000199898
CHEBI:107170
1-(4-methyl-3-nitrophenyl)-3-[(4-methylphenyl)methyl]thiourea
AKOS003310168
HMS2533D24
CHEMBL1602768
Q27185225
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
thioureasCompounds of general formula RR'NC(=S)NR''R'''.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (8)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
TDP1 proteinHomo sapiens (human)Potency18.84520.000811.382244.6684AID686978; AID686979
PINK1Homo sapiens (human)Potency44.66842.818418.895944.6684AID624263
ParkinHomo sapiens (human)Potency44.66840.819914.830644.6684AID624263
polyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)Potency0.79431.000012.232631.6228AID1452
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency89.12510.354828.065989.1251AID504847
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency4.92880.00798.23321,122.0200AID2546; AID2551
gemininHomo sapiens (human)Potency4.10950.004611.374133.4983AID624296
Guanine nucleotide-binding protein GHomo sapiens (human)Potency5.62341.995325.532750.1187AID624287
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (5)

Processvia Protein(s)Taxonomy
negative regulation of inflammatory response to antigenic stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
renal water homeostasisGuanine nucleotide-binding protein GHomo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein GHomo sapiens (human)
regulation of insulin secretionGuanine nucleotide-binding protein GHomo sapiens (human)
cellular response to glucagon stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (2)

Processvia Protein(s)Taxonomy
G protein activityGuanine nucleotide-binding protein GHomo sapiens (human)
adenylate cyclase activator activityGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]